This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations on AI augmented diagnostics for cancer and infectious diseases. The increase in clinical utility of liquid biopsies and other diagnostic assays, which is driven by AI has been discussed. The TOE issue also highlights developments in enabling t...

Single cell genomic and proteomics tools have gained significant importance in the past 2 years. The year 2018 was particularly very active with a lot of platforms made available by both established life sciences tools companies and start-ups. 10X Genomics and Fluidigm have demonstrated the potential for high-throughput single cell applications. Th...

This edition of the Genetic Technology TOE depicts life sciences trends across genomics. Discovery of genetic risk factors for common complex diseases, an artificial intelligence platform for assembling biological data, advancing precision oncology via whole genome sequencing, and cutting edge adjacent technologies have been profiled. Ongoing clini...

This edition of the Drug Discovery TOE depicts trends across clinical pharmacogenomics exemplified with prospective innovations worldwide. Although still much research needs to be carried out to leverage genomic information in the development of more personalized and cost-effective strategies in drug discovery and development, the impact of clinica...

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across biotherapeutics and genomics. The corresponding patent scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emp...

This edition of the Genetic Technology TOE depicts a range of innovations across personalized genomics specifically across the Indian subcontinent. It provides an overview of some of the major strategic alliances that are happening in India. The companies profiled in this issues, are the current key participants in the personalized genomics space. ...

This issue profiles personalized treatment for prostate cancer patients, personal genomics that paves the way for future medicine and health, and gene therapy for ophthalmic diseases.

This issue of Vital Signs, released on November 23, 2009, provides a strategic overview of trends in pharmacogenomic testing and drug development. Additionally, a company spotlight is provided for Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative new therapies that treat and prevent ...

This issue of Vital Signs, released on February 4, 2008, provides an strategic overview of the integration of genomics technology in proteomics analysis. Additionally, a company spotlight is provided for MSM Protein Technologies, an emerging biotechnology company with a suite of tools for drug discovery of functional antibodies and proteins against...